Rationale for contemporary domestic and international approaches to managing patients with ATTR-amyloid cardiomyopathy
https://doi.org/10.21518/ms2025-035
Abstract
ATTR amyloid cardiomyopathy (AC) is a complex and under-recognized condition that has been attracting increasing attention from the medical community in recent years. This is due to a deeper understanding of the disease’s pathogenesis, an expansion of data on its clinical presentation, and the emergence of more accurate diagnostic tools. Nevertheless, AC remains one of the causes of chronic heart failure (CHF) with preserved left ventricular ejection fraction (LVEF), especially prevalent among elderly patients. Moreover, one of the main challenges is late diagnosis, caused by both the non-specificity of symptoms and insufficient vigilance among physicians. As a consequence, this leads to disease progression and a poorer prognosis. Therefore, timely identification of both cardiac and extracardiac symptoms of ATTR amyloidosis is crucial for improving diagnostic accuracy and initiating appropriate therapy. The treatment of amyloidosis includes pathogenetic (anti-amyloid) and symptomatic therapies. Currently, tafamidis is the first drug used for the treatment of ATTR amyloidosis and is recommended for patients with both hereditary and “wild-type” forms of the disease. Amyloid cardiomyopathy is an interdisciplinary problem that requires heightened awareness not only from cardiologists but also from general practitioners and specialists in related fields. The optimization of diagnostic algorithms and the implementation of innovative therapeutic approaches are key objectives for reducing the time to diagnosis and initiating timely treatment. The recommendations discussed in this article can serve as a basis for improving the quality of care provided to patients with AC.
About the Authors
G. E. EgorovaRussian Federation
Glafira E. Egorova, Student, Medical Faculty
51, Troitsky Ave., Arkhangelsk, 163000, Russia
D. I. Kalinin
Russian Federation
Denis I. Kalinin, Student, Medical Faculty
51, Troitsky Ave., Arkhangelsk, 163000, Russia
S. V. Yureva
Russian Federation
Svetlana V. Yureva, Cand. Sci. (Med.), Associate Professor, Department of Family Medicine; Cardiologist
51, Troitsky Ave., Arkhangelsk, 163000, Russia
99, Troitsky Ave., Arkhangelsk, 163000, Russia
A. V. Komelkova
Russian Federation
Anastasia V. Komelkova, Student, Medical Faculty
51, Troitsky Ave., Arkhangelsk, 163000, Russia
A. S. Ipatov
Russian Federation
Alexey S. Ipatov, Student, Medical Faculty
51, Troitsky Ave., Arkhangelsk, 163000, Russia
D. A. Kokovina
Russian Federation
Daria A. Kokovina, Student, Medical Faculty
51, Troitsky Ave., Arkhangelsk, 163000, Russia
A. I. Yureva
Russian Federation
Anastasia I. Yureva, Student, Medical Faculty
4, Dolgorukovskaya St., Moscow, 127006, Russia
References
1. Vaihanskaya TG. Transthyretin-Amyloid Cardiomyopathy: Criteria for NonInvasive Diagnosis, Clinical Сase Report. Kardiologija v Belarusi. 2023;15(4):492–510. (In Russ.) https://doi.org/10.34883/PI.2023.15.4.006.
2. Oerlemans MIFJ, Rutten KHG, Minnema MC, Raymakers RAP, Asselbergs FW, de Jonge N. Cardiac amyloidosis: the need for early diagnosis. Neth Heart J. 2019;27(11):525–536. https://doi.org/10.1007/s12471-019-1299-1.
3. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–2654. https://doi.org/10.1016/S0140-6736(15)01274-X.
4. Rameev VV, Myasnikov RP, Vinogradov PP, Kozlovskaya LV, Moiseev SV, Fomicheva EI. Systemic ATTR-Amyloidosis, a Rare Form of Internal Organ Damage. Rational Pharmacotherapy in Cardiology. 2019;15(3):349–358. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-3-349-358.
5. Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat. 2019;40(1):90–96. https://doi.org/10.1002/humu.23669.
6. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: A systematic review and clinical experience. ESC Heart Fail. 2018;5(5):772–779. https://doi.org/10.1002/ehf2.12308.
7. Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W et al. Atrial fibrillation in transthyretin cardiac amyloidosis: Predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6(9):1118–1127. https://doi.org/10.1016/j.jacep.2020.04.019.
8. Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–2767. https://doi.org/10.1093/eurheartj/ehaa170.
9. Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2022;43(Suppl. 2):595–604. https://doi.org/10.1007/s10072-020-04889-2.
10. Golbus JR, Wells JM, Dickinson MG, Hummel SL. Importance of Genetic Testing in the Diagnosis of Transthyretin Cardiac Amyloidosis. Am J Med. 2018;131(7):e303–е304. https://doi.org/10.1016/j.amjmed.2018.02.005.
11. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019;6(6):1128–1139. https://doi.org/10.1002/ehf2.12518.
12. Patel KS, Hawkins PN. Cardiac amyloidosis: Where are we today? J Intern Med. 2015;278(2):126–144. https://doi.org/10.1111/joim.12383.
13. Терещенко СН, Насонова СН, Жиров ИВ, Саидова МА, Аншелес АА, Шария МА и др. Амилоидоз сердца. М.; 2022. 36 с. Режим доступа: https://scardio.ru/content/activities/2024/04102024_10.pdf.
14. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. https://doi.org/10.1136/jnnp-2014-308724.
15. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709–716. https://doi.org/10.1016/j.jchf.2019.04.010.
16. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the art review. J Am Coll Cardiol. 2019;73(22):2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003.
17. Belfeki N, Ghriss N, Monchi M, Moini C. State of the Art of cardiac amyloidosis. Biomedicines. 2023;11(4):1045. https://doi.org/10.3390/biomedicines11041045.
18. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. https://doi.org/10.1161/CIR.0000000000000792.
19. Gościniak P, Baron T, Milczarek S, Kostkiewicz M, Machaliński B. Updates for the diagnosis and management of cardiac amyloidosis. Adv Clin Exp Med. 2022;31(2):175–185. https://doi.org/10.17219/acem/142252.
20. Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA et al. Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 2018;72(17):2040–2050. https://doi.org/10.1016/j.jacc.2018.07.092.
21. Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S et al. Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies. Eur J Heart Fail. 2020;22(3):507–515. https://doi.org/10.1002/ejhf.1742.
22. Eldhagen P, Berg S, Lund LH, Sörensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2021;289(6):895–905. https://doi.org/10.1111/joim.13222.
23. Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH. Association between ruptured distal biceps tendonтand wild-type transthyretin cardiac amyloidosis. JAMA. 2017;318(10):962–963. https://doi.org/10.1001/jama.2017.9236.
24. Alqarni A, Aljizeeri A, Bakhsh AM, El-Zeftawy HAM, Farghaly HR, Alqadhi MAM et al. Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts. Diagnostics. 2024;14(2):212. https://doi.org/10.3390/diagnostics14020212.
25. Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6(1):1–7. https://doi.org/10.1002/ana.410060102.
26. Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol.1995;32(1):45–59. Available at: https://pubmed.ncbi.nlm.nih.gov/7878478/.
27. Dorbala Sh, Ando Yu, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065–2123. https://doi.org/10.1007/s12350-019-01760-6.
28. Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(4):909–920. https://doi.org/10.1016/j.jcmg.2019.10.011.
29. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Fail. 2019;6(5):1041–1051. https://doi.org/10.1002/ehf2.12511.
30. Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. J Am Coll Cardiol Img. 2020;13(6):1368–1383. https://doi.org/10.1016/j.jcmg.2019.07.015.
31. Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Martinez-Naharro A et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging. 2019;12(5):823–833. https://doi.org/10.1016/j.jcmg.2018.02.016.
32. Antukh D, Shchekochikhin D, Rosina T, Mershina E, Larina O, Pasha S et al. Scintigraphy false-positive results for cardiac amyloidosis in a patient with Danon disease. Clin Case Rep. 2021;9(8):e04652. https://doi.org/10.1002/ccr3.4652.
33. Chimenti C, Alfarano M, Maestrini V, Galea N, De Vincentis G, Verardo R et al. False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy. ESC Heart Fail. 2021;8(4):3387–3391. https://doi.org/10.1002/ehf2.13339.
34. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. https://doi.org/10.1161/CIR.0000000000000792.
35. Wisniowski B, Wechalekar A. Confirming the Diagnosis of Amyloidosis. Acta Haematol. 2020;143(4):312–321. https://doi.org/10.1159/000508022.
36. Nativi-Nicolau J, Sarswat N, Fajardo J, Finkel M, Abdulsattar Y, Castaño A et al. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates. Clin Med Insights Cardiol. 2021;15:11795468211015230. https://doi.org/10.1177/11795468211015230.
37. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. https://doi.org/10.1056/NEJMoa1805689.
38. Davies DR, Redfield MM, Scott CG, Minamisawa M, Grogan M, Dispenzieri A et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2022;7(10):1036–1044. https://doi.org/10.1001/jamacardio.2022.1781.
39. Redfield M, Borlaug B. Heart failure with preserved ejection fraction. A review. JAMA. 2023;329(10):827–838. https://doi.org/10.1001/jama.2023.2020.
40. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554–1568. https://doi.org/10.1093/eurheartj/ehab072.
41. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO et al. 2023 ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076–1126. https://doi.org/10.1016/j.jacc.2022.11.022.
42. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(10):1169–1186. https://doi.org/10.1002/ejhf.1531.
43. Lysenko LV, Rameev VV, Moiseev SV, Blagova OV, Bogdanov EI, Gendlin GE et al. Clinical Guidelines for Diagnosis and Treatment of Systemic Amyloidosis. Clinical Pharmacology and Therapy. 2020;29(1):13–24. (In Russ.) https://doi.org/10.32756/0869-5490-2020-1-13-24.
44. Moiseev SV, Rameev VV. Tafamidis in Transthyretin Amyloid Cardiomyopathy. Clinical Pharmacology and Therapy. 2021;30(2):44–50. (In Russ.) https://doi.org/10.32756/0869-5490-2021-2-44-50
Review
For citations:
Egorova GE, Kalinin DI, Yureva SV, Komelkova AV, Ipatov AS, Kokovina DA, Yureva AI. Rationale for contemporary domestic and international approaches to managing patients with ATTR-amyloid cardiomyopathy. Meditsinskiy sovet = Medical Council. 2025;(6):241-249. (In Russ.) https://doi.org/10.21518/ms2025-035